CDKN1B and hepatocellular carcinoma: Taken together, the data from this investigation strongly suggest that the inhibition of SKP2 or the reactivation of p27KIP1 might represent a valuable therapeutic option against HCC lesions characterized by the activation of the FASN cascade.